https://www.biopharm.org.tw
+886-2-2655-8135
services@biopharm.org.tw
Main Products/ Services/ Pipelines & Platforms
TaiMed Biologics was founded in 2007 and has devoted itself as a leading biopharmaceutical developer and manufacturer of innovative biologics drugs. TaiMed has developed a first-in-class anti-HIV antibody drug ibalizumab (Trogarzo®) which the US FDA and EMA approved in 2018 and 2019, respectively. Leveraging our experience developing Trogarzo® and other novel, long-acting anti-HIV monoclonal antibodies in the pipeline, TaiMed has also become a Contract Development and Manufacturing Organization (CDMO) offering manufacturing solutions that will enable partners to discover, develop and manufacture biologics from the bench to market. We strive to ensure that our clients’ projects are treated as our own with the same high standards with respect to quality, cost and logistical requirements. Please contact us at cdmo@taimedbio.com for additional information.
Business Interests
▪ Out-Licensing novel, long-acting anti-HIV monoclonal antibodies. ▪ Contract Manufacturing ▪ Contract Development and Manufacturing
Contact Information
Taiwan (CDMO)
Glory Lin
Senior Manager, Manufacturing and Technology
+886-3-621-2355 #210
cdmo@taimedbio.com
United States (Out-licensing)
Jonathan Ho
Senior Director, Business Development & Alliance Management
+1-917-803-7770
jho@taimedbio.com